29,567 Shares in Vera Therapeutics, Inc. $VERA Acquired by J. Safra Sarasin Holding AG

J. Safra Sarasin Holding AG bought a new position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 29,567 shares of the company’s stock, valued at approximately $697,000.

Several other large investors have also recently added to or reduced their stakes in VERA. California State Teachers Retirement System increased its stake in Vera Therapeutics by 19.9% during the 4th quarter. California State Teachers Retirement System now owns 40,640 shares of the company’s stock worth $1,719,000 after buying an additional 6,749 shares during the period. GAMMA Investing LLC increased its stake in Vera Therapeutics by 1,779.1% during the 1st quarter. GAMMA Investing LLC now owns 8,287 shares of the company’s stock worth $199,000 after buying an additional 7,846 shares during the period. Rhumbline Advisers increased its stake in Vera Therapeutics by 7.9% during the 1st quarter. Rhumbline Advisers now owns 63,189 shares of the company’s stock worth $1,518,000 after buying an additional 4,600 shares during the period. Bank of New York Mellon Corp increased its stake in Vera Therapeutics by 1.2% during the 1st quarter. Bank of New York Mellon Corp now owns 143,665 shares of the company’s stock worth $3,451,000 after buying an additional 1,717 shares during the period. Finally, GW&K Investment Management LLC grew its holdings in Vera Therapeutics by 35.2% during the 1st quarter. GW&K Investment Management LLC now owns 252,240 shares of the company’s stock worth $6,059,000 after acquiring an additional 65,635 shares in the last quarter. 99.21% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on VERA shares. JPMorgan Chase & Co. lowered their price target on shares of Vera Therapeutics from $56.00 to $53.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vera Therapeutics in a report on Thursday, September 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Saturday, September 27th. Finally, Wolfe Research reiterated a “peer perform” rating on shares of Vera Therapeutics in a report on Monday, August 4th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $63.00.

Vera Therapeutics Stock Up 3.3%

Shares of NASDAQ:VERA opened at $30.14 on Friday. The stock has a market cap of $1.92 billion, a P/E ratio of -8.42 and a beta of 1.23. The firm has a fifty day moving average price of $23.44 and a 200 day moving average price of $23.07. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.38). During the same period in the previous year, the business posted ($0.62) EPS. Sell-side analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.